Quanterix Corporation filed a 510(k) pre‑market notification with the U.S. Food and Drug Administration on February 3, 2026 for its LucentAD platform, a multi‑analyte algorithmic blood test that detects Alzheimer’s disease by measuring five biomarkers—p‑Tau 217, Aβ42, Aβ40, GFAP, and NfL—using the company’s proprietary Simoa® technology.
The LucentAD test builds on a Breakthrough Device designation that the FDA granted in 2024, a designation that expedites review for devices that address unmet medical needs. The algorithm combines the five biomarkers to improve diagnostic accuracy over single‑analyte tests, a feature that differentiates it from competitors such as Fujirebio’s Lumipulse G and Labcorp’s recent launches.
The Alzheimer’s diagnostics market is projected to reach $10 billion by 2026, with the blood‑based biomarker segment growing faster than other modalities. Quanterix’s multi‑biomarker approach positions it to capture a share of this expanding market, while the competitive landscape includes several other blood‑test developers that rely on fewer analytes or different biomarker panels.
Financially, Quanterix has reported negative earnings per share in recent quarters and is targeting cash‑flow breakeven by 2026. The 510(k) filing is a key step toward commercializing a product that could generate significant revenue, potentially offsetting current profitability challenges. The company’s stock has shown a positive market reaction to the filing, reflecting investor optimism about the regulatory progress and future revenue potential.
CEO Masoud Toloue emphasized the strategic importance of the LucentAD platform, noting that “the breakthrough designation validates the need for accessible, non‑invasive p‑Tau 217 testing” and that the multi‑marker approach “confirms our next phase in the evolution of blood‑based testing for Alzheimer’s.”
The market reacted positively to the filing, with analysts noting the regulatory milestone and the potential to tap into a rapidly growing diagnostics market, while also acknowledging the company’s ongoing financial challenges and the competitive environment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.